Related Experiment Video
Updated: Dec 27, 2025

An Alkali-burn Injury Model of Corneal Neovascularization in the Mouse
Published on: April 7, 2014
Keratocytes promote corneal neovascularization through VEGFr3 induced by PPARα-inhibition
Xue Wang1, Liying Tang2, Zhaoqiang Zhang2
1Aier School of Ophthalmology, Central South University, Changsha, 410015, China; Eye Institute of Xiamen University, Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, Medical College, Xiamen University, Xiamen, Fujian, China.
Abstract:
As the peroxisome proliferator - activated receptor alpha (PPARα) agonist, fenofibrate has been widely used to be a good lipid-regulating drug in the clinical application. In this study, we investigated the mechanism by which keratocytes inhibit the corneal neovascularization (CNV) through PPARα - activation. To do this, the CNV model was established by alkali burn, followed by being divided into three groups including control, fenofibrate and vehicle group. The expression of VEGFr3, MMP13 and PPARα in corneas of normal mouse and alkali-burned mouse was determined via quantitative RT- PCR (qRT-PCR) and Western blot analysis (WB). The CNV area was observed under a slit lamp microscope. The location of PPARα expression in the corneas was determined via immunohistochemistry. In cultured primary keratocytes, the effect of fenofibrate on PPARα, VEGFr3 and MMP13 expression was determined by qRT-PCR and WB. Besides, PPARα knockout (PPARα-/-) mouse CNV and keratocytes model were established to further confirm the effect of PPARα on VEGFr3 and MMP13 expression. We found that PPARα was expressed in epithelium, stroma and endothelium of the normal cornea, however, with relatively low level in the corneal stroma. Meanwhile, its expression was decreased markedly in the cornea during the stage of CNV formation. After treatment of fenofibrate, PPARα expression was promoted and the expression of VEGFr3 and MMP13 was inhibited in both CNV mice model and primary keratocytes, and CNV areas were decreased in CNV mice model. However, the results in PPARα-/- CNV and keratocytes model were opposite. Our results suggest that keratocytes could promote the expression of VEGFr3 and MMP13, and CNV formation through PPARα downregulation.
Insights
Fenofibrate activates peroxisome proliferator-activated receptor alpha (PPARα), inhibiting corneal neovascularization (CNV). This study reveals PPARα downregulation promotes CNV by increasing VEGFr3 and MMP13 expression in keratocytes.
Area of Science:
- Ophthalmology
- Molecular Biology
- Pharmacology
Background:
- Corneal neovascularization (CNV) is a pathological process involving new blood vessel growth in the cornea.
- Peroxisome proliferator-activated receptor alpha (PPARα) is a nuclear receptor involved in lipid metabolism and inflammation.
- Fenofibrate, a PPARα agonist, is clinically used for lipid regulation.
Purpose of the Study:
- To investigate the mechanism by which keratocytes inhibit corneal neovascularization (CNV) through PPARα activation.
- To determine the role of PPARα in regulating VEGFr3 and MMP13 expression during CNV.
Main Methods:
- Established a mouse model of CNV using alkali burn.
- Administered fenofibrate or vehicle to CNV mice and analyzed corneal tissue.
- Utilized quantitative RT-PCR (qRT-PCR) and Western blot (WB) to assess gene and protein expression (PPARα, VEGFr3, MMP13).
- Performed immunohistochemistry to localize PPARα expression.
- Investigated fenofibrate's effects on primary cultured keratocytes.
- Utilized PPARα knockout (PPARα-/-) mice to confirm findings.
Main Results:
- PPARα expression was decreased in corneas during CNV formation.
- Fenofibrate treatment upregulated PPARα and downregulated VEGFr3 and MMP13, reducing CNV area.
- Inhibition of PPARα in knockout models reversed these effects.
- Fenofibrate's effects were consistent in both in vivo and in vitro keratocyte models.
Conclusions:
- Keratocytes play a role in CNV formation.
- PPARα downregulation in keratocytes promotes CNV by increasing VEGFr3 and MMP13 expression.
- PPARα activation, potentially via fenofibrate, represents a therapeutic strategy for inhibiting CNV.
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
Mechanism of Angiogenesis

